STLN
The Oncology Institute, Inc.
NasdaqCM Healthcare United States
6,30 $US
-0.79% today
+71.66% YTD · +65.35% 1Y
2
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
16
Hedge funds tracked
Latest available SEC 13F filings
62
/ 100
STRONG

Analysis The Oncology Institute, Inc. (STLN) — Kairos Score 62/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About The Oncology Institute, Inc.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Key info

👔
CEO
Dr. Daniel Virnich FACHE, M.B.A., M.D.
📍
HQ
18000 Studebaker Road, Suite 800, Cerritos, CA, 90703, United States
👥
Employees
641
💰
Market cap
631 392 200,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

2 transactions — 1 buys and 1 sales reported by The Oncology Institute, Inc. executives.

HB
Hively Brad
2026-08-21
Sell
CJ
Chernett Jorey
2026-08-14
Buy

🏦 Hedge Funds

16 institutional funds report a position on STLN in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD GROUP INC
GEODE CAPITAL MANAGEMENT, LLC
GOLDMAN SACHS GROUP INC

📰 Recent news

6 recent articles on STLN.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as The Oncology Institute, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of STLN on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 2 insider transactions over 90 days
✅ All 16 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year